PMID- 19232551
OWN - NLM
STAT- MEDLINE
DCOM- 20100225
LR  - 20090911
IS  - 1873-0183 (Electronic)
IS  - 1568-9972 (Linking)
VI  - 9
IP  - 1
DP  - 2009 Sep
TI  - Beta2-glycoprotein I and annexin A5 phospholipid interactions: artificial and 
      cell membranes.
PG  - 5-10
LID - 10.1016/j.autrev.2009.02.025 [doi]
AB  - The aim of this report was an overview of beta2-glycoprotein I (beta2-GPI)- and 
      annexin A5 (AnxA5)-phospholipid interactions including candidate beta2-GPI 
      receptors, and their relevance to the investigation of physiological/pathological 
      processes. Both beta2-GPI and AnxA5 have thrombomodulatory functions in vivo and 
      their antigenicity is particularly important for thrombotic manifestations and 
      pregnancy complications in antiphospholipid syndrome. Specific elements of 
      beta2-GPI- and AnxA5-phospholipid interactions are different. The crucial 
      elements for beta2-GPI are conformational change and dimerization, both of which 
      are also required and necessary for receptor signaling, leading to the 
      prothombotic state. AnxA5 differs in its ability to crystallize into a protective 
      shield, the disruption of which seems to be the major prothrombotic mechanism. 
      These differences may explain some of the functional consequences of both 
      molecules seen in the pathological conditions. Future alternative therapies of 
      antiphospholipid syndrome are proposed to be based on the expanding knowledge of 
      beta2-GPI- and AnxA5-phospholipid interactions, specifically antagonizing 
      beta2-GPI receptors, as well as inhibiting their signaling pathways.
FAU - Frank, Mojca
AU  - Frank M
AD  - Department of Rheumatology, University Medical Centre Ljubljana, Vodnikova 62, 
      Ljubljana, Slovenia.
FAU - Sodin-Semrl, Snezna
AU  - Sodin-Semrl S
FAU - Irman, Spela
AU  - Irman S
FAU - Bozic, Borut
AU  - Bozic B
FAU - Rozman, Blaz
AU  - Rozman B
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20090216
PL  - Netherlands
TA  - Autoimmun Rev
JT  - Autoimmunity reviews
JID - 101128967
RN  - 0 (Annexin A5)
RN  - 0 (Anticoagulants)
RN  - 0 (Membranes, Artificial)
RN  - 0 (beta 2-Glycoprotein I)
SB  - IM
MH  - Allosteric Regulation/drug effects/immunology
MH  - Annexin A5/immunology/*metabolism
MH  - Anticoagulants/immunology/*metabolism/therapeutic use
MH  - Antiphospholipid Syndrome/drug therapy/*immunology/metabolism/physiopathology
MH  - Cell Membrane/immunology
MH  - Female
MH  - Humans
MH  - Membranes, Artificial
MH  - Pregnancy
MH  - Pregnancy Complications/drug therapy/*immunology/metabolism/physiopathology
MH  - Signal Transduction/drug effects/immunology
MH  - beta 2-Glycoprotein I/immunology/*metabolism
RF  - 40
EDAT- 2009/02/24 09:00
MHDA- 2010/02/26 06:00
CRDT- 2009/02/24 09:00
PHST- 2009/01/07 00:00 [received]
PHST- 2009/02/11 00:00 [accepted]
PHST- 2009/02/24 09:00 [entrez]
PHST- 2009/02/24 09:00 [pubmed]
PHST- 2010/02/26 06:00 [medline]
AID - S1568-9972(09)00061-5 [pii]
AID - 10.1016/j.autrev.2009.02.025 [doi]
PST - ppublish
SO  - Autoimmun Rev. 2009 Sep;9(1):5-10. doi: 10.1016/j.autrev.2009.02.025. Epub 2009 
      Feb 16.